{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:48:14Z","timestamp":1794354494719,"version":"4.9.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mto.2016.21","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T10:43:29Z","timestamp":1474973009000},"page":"16021","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy"],"prefix":"10.1016","volume":"3","author":[{"given":"Catherine","family":"Dold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Rodriguez Urbiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Wollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Bellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidelinde","family":"Fiegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kimpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mto.2016.21_bib1","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(12)60595-9","article-title":"Breast and cervical cancer in 187 countries between 1980 and 2010","volume":"379","author":"Ferlay","year":"2012","journal-title":"Lancet"},{"key":"10.1038\/mto.2016.21_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mto.2016.21_bib3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ctrv.2010.12.003","article-title":"The emerging role of viruses in the treatment of solid tumours","volume":"37","author":"Bourke","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/mto.2016.21_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1038\/mto.2016.21_bib5","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1128\/JVI.03276-13","article-title":"VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications","volume":"88","author":"Tober","year":"2014","journal-title":"J Virol"},{"key":"10.1038\/mto.2016.21_bib6","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2016.21_bib7","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/JVI.00709-15","article-title":"Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors","volume":"89","author":"Wollmann","year":"2015","journal-title":"J Virol"},{"key":"10.1038\/mto.2016.21_bib8","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1038\/mto.2016.21_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"key":"10.1038\/mto.2016.21_bib10","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1038\/sj.onc.1209042","article-title":"VSV-tumor selective replication and protein translation","volume":"24","author":"Barber","year":"2005","journal-title":"Oncogene"},{"key":"10.1038\/mto.2016.21_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/713803696","article-title":"Vesicular stomatitis virus (VSV) therapy of tumors","volume":"50","author":"Balachandran","year":"2000","journal-title":"IUBMB Life"},{"key":"10.1038\/mto.2016.21_bib12","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1073\/pnas.0901329106","article-title":"Impaired interferon signaling is a common immune defect in human cancer","volume":"106","author":"Critchley-Thorne","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mto.2016.21_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1038\/mto.2016.21_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1038\/mto.2016.21_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/cgt.2013.55","article-title":"Overcoming cancer cell resistance to VSV oncolysis with JAK1\/2 inhibitors","volume":"20","author":"Escobar-Zarate","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2016.21_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/srep02375","article-title":"Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy","volume":"3","author":"Liu","year":"2013","journal-title":"Sci Rep"},{"key":"10.1038\/mto.2016.21_bib17","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1126\/science.282.5396.2079","article-title":"Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus","volume":"282","author":"Cao","year":"1998","journal-title":"Science"},{"key":"10.1038\/mto.2016.21_bib18","doi-asserted-by":"crossref","first-page":"14297","DOI":"10.1128\/JVI.79.22.14297-14308.2005","article-title":"O Mannosylation of alpha-dystroglycan is essential for lymphocytic choriomeningitis virus receptor function","volume":"79","author":"Imperiali","year":"2005","journal-title":"J Virol"},{"key":"10.1038\/mto.2016.21_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/mthe.2001.0446","article-title":"An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression","volume":"4","author":"Hemminki","year":"2001","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.21_bib20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1126\/science.282.5396.2079","article-title":"Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus","volume":"282","author":"Cao","year":"1998","journal-title":"Science"},{"key":"10.1038\/mto.2016.21_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1083\/jcb.200104103","article-title":"Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan","volume":"155","author":"Kunz","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1038\/mto.2016.21_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.virol.2004.05.009","article-title":"Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus","volume":"325","author":"Kunz","year":"2004","journal-title":"Virology"},{"key":"10.1038\/mto.2016.21_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2009.10.086","article-title":"Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models","volume":"116","author":"Capo-chichi","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1038\/mto.2016.21_bib24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"10.1038\/mto.2016.21_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2009.088","article-title":"Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy","volume":"21","author":"Saloura","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2016.21_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.virol.2012.11.014","article-title":"Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling","volume":"436","author":"Moerdyk-Schauwecker","year":"2013","journal-title":"Virology"},{"key":"10.1038\/mto.2016.21_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.surg.2012.09.003","article-title":"Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus","volume":"153","author":"Blackham","year":"2013","journal-title":"Surgery"},{"key":"10.1038\/mto.2016.21_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2015.08.003","article-title":"Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1","volume":"485","author":"Cataldi","year":"2015","journal-title":"Virology"},{"key":"10.1038\/mto.2016.21_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/gt.2014.83","article-title":"Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model","volume":"22","author":"Ruotsalainen","year":"2015","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2016.21_bib30","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.4049\/jimmunol.0800596","article-title":"Local type I IFN receptor signaling protects against virus spread within the central nervous system","volume":"182","author":"Detje","year":"2009","journal-title":"J Immunol"},{"key":"10.1038\/mto.2016.21_bib31","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mto.2016.21_bib32","doi-asserted-by":"crossref","first-page":"ofv082","DOI":"10.1093\/ofid\/ofv082","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090)","volume":"2","author":"Fuchs","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1038\/mto.2016.21_bib33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1038\/mto.2016.21_bib34","article-title":"A Recombinant vesicular stomatitis virus ebola vaccine\u2013preliminary report","author":"Regules","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/mto.2016.21_bib35","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe\u2013preliminary report","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1038\/mto.2016.21_bib36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.cgt.7700510","article-title":"Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer","volume":"9","author":"Bennett","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2016.21_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.21_bib38","first-page":"3818","article-title":"Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells","volume":"57","author":"Marth","year":"1997","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2016.21_bib39","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1210\/jc.2004-0044","article-title":"Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells","volume":"89","author":"Choi","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/mto.2016.21_bib40","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JVI.02511-10","article-title":"Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism","volume":"85","author":"Muik","year":"2011","journal-title":"J Virol"},{"key":"10.1038\/mto.2016.21_bib41","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1128\/JVI.70.4.2318-2323.1996","article-title":"The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus","volume":"70","author":"Schnell","year":"1996","journal-title":"J Virol"},{"issue":"Pt 11","key":"10.1038\/mto.2016.21_bib42","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1099\/vir.0.023978-0","article-title":"Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity","volume":"91","author":"Hoffmann","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1038\/mto.2016.21_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J Virol Methods"},{"key":"10.1038\/mto.2016.21_bib44","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/sj.mt.6300155","article-title":"Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene","volume":"15","author":"Miletic","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.21_bib45","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/JVI.00666-08","article-title":"Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46","volume":"83","author":"Hermann","year":"2009","journal-title":"J Virol"},{"key":"10.1038\/mto.2016.21_bib46","first-page":"480","article-title":"50% end-point calculation","volume":"162","author":"Kaerber","year":"1931","journal-title":"Arch Exp Pathol Pharmakol"},{"key":"10.1038\/mto.2016.21_bib47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/jcm.9.4.471-475.1979","article-title":"Assay of human interferon in Vero cells by several methods","volume":"9","author":"Ferreira","year":"1979","journal-title":"J Clin Microbiol"},{"key":"10.1038\/mto.2016.21_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/spmg.1.2.16606","article-title":"Enhanced chemiluminescence (ECL) for routine immunoblotting: An inexpensive alternative to commercially available kits","volume":"1","author":"Mruk","year":"2011","journal-title":"Spermatogenesis"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T03:43:23Z","timestamp":1657338203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770516300584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":48,"alternative-id":["S2372770516300584"],"URL":"https:\/\/doi.org\/10.1038\/mto.2016.21","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"article-number":"16021"}}